Facebook
Twitter
LinkedIn
Forward25th International Prostate Cancer Update
Patterns of care in prostate cancer (PCa) have changed tremendously in the past 25 years, altering the way patients with this tumor present and how they are evaluated before and after diagnosis. With the use of new and combined treatments, the frequency and variety of complications have differed from those previously reported. Advances have been made in PCa imaging, biopsy methodology, in understanding causative factors and disease, in treatment-related quality of life, and in predicting the behavior of individual tumors using risk strata. Despite these advances, no consensus has emerged regarding the optimal treatment for the most common patient with PCa.
This activity seeks to educate urologists and other healthcare professionals about the latest advances in the prevention, screening, diagnosis, and treatment of PCa. The International Prostate Cancer Update (IPCU) educational planning committee has identified the educational gaps between recent research in PCa and its integration into professional practice at the international, national, and community levels.
Target Audience
This activity has been developed and is intended for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the treatment of prostate cancer.
Learning Objectives
This educational initiative aims to reach urologists, oncologists, urologic oncologists, and nurses. Upon completion of the conference, participants will be able to:
- Evaluate the growing use of biomarkers in prostate cancer detection
- Compare the use of various imaging and other advanced technologies in treating localized prostate cancer
- Integrating available hormonal, cytotoxic and immunotherapeutic agents for advanced and castration-resistant prostate cancer
- Assess the options for personalizing treatment and sequencing new therapies in individual patients
- Define how the treatment of prostate cancer has evolved in the last 25 years
Dislosure information provided onsite.
Program Chair-E. David Crawford, MD
Professor of Surgery, Urology and Radiation Oncology
E. David Crawford Endowed Chair in Urologic Oncology
University of Colorado
Denver School of Medicine
Aurora, Colorado
Faculty
Per-Anders Abrahamsson, MD, PhD
Lund University
Malmo, Sweden
Gerald L. Andriole, MD
Washington University School of Medicine
St. Louis, MO
Michael K. Brawer, MD
Myriad Genetics, Inc.
Salt Lake City, UT
Raoul S. Concepcion, MD
Urology Associates P.C.
Nashville, TN
Frans M.J. Debruyne, MD, PhD
Andros Men’s and Gynos Women’s Health Institutes
Arnhem, The Netherlands
James A. Eastham, MD
Memorial Sloan-Kettering Cancer Center
New York, NY
Mark Emberton, MD
University College London
London, United Kingdom
Stephen J. Freedland, MD
Duke University Medical Center
Durham, NC
Marc B. Garnick, MD
Harvard University
Boston, MA
Leonard G. Gomella, MD
Thomas Jefferson University
Philadelphia, PA
Thomas E. Keane, MBBCh
Medical University of South Carolina
Charleston, SC
Laurence Klotz, MD
Sunnybrook Health Sciences Centre
Toronto, ON, Canada
Jason L. Letran, MD
University of Santos Tomas
Manila, The Philippines
M. Scott Lucia, MD
University of Colorado, Denver School of Medicine
Aurora, CO
Arturo Mendoza-Valdés, MD
Urólogo. Hospital Médica Sur
Tialpan, México
Brian J. Moran, MD
Chicago Prostate Center
Westmont, IL
Abraham Morgentaler, MD
Men’s Health Boston
Boston, MA
Alan W. Partin, MD, PhD
Johns Hopkins Medical Institutions
Baltimore, MD
Daniel P. Petrylak, MD
Yale Cancer Center
New Haven, CT
Christopher R. Porter, MD, FACS
Virginia Mason Medical Center
Seattle, WA
Matt T. Rosenberg, MD
MidMichigan Health Centers
Jackson, MI
Neal D. Shore, MD
Atlantic Urology Clinics, LLC
Myrtle Beach, SC
Nelson N. Stone, MD
Mount Sinai School of Medicine
New York, NY
Priya N. Werahera, PhD
University of Colorado, Denver
Aurora, CO
Michael J. Zelefsky, MD
Memorial Sloan-Kettering Cancer Center
New York, NY
Available Credit
- 14.25 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™